New Phase 3 findings published in the Journal of the Prevention of Alzheimer’s Disease show that Alzheon’s investigational agent tramiprosate (ALZ-801) may offer cognitive and functional benefits to patients with mild disease. Researchers analyzed APOE4/4 homozygotes based on disease severity and found that patients in the mild disease at baseline subgroup showed larger efficacy signals. Moreover, the cognitive effect of tramiprosate in patients with mild disease increased significantly with time, suggesting a potential disease-modifying effect, the researchers observed. According to the authors, this clinical profile is consistent with the recently discovered molecular mechanism of action, where tramiprosate inhibited monomer aggregation and formation of toxic Aβ oligomers.Next Story
Phase 3 Results Suggest Promise of Investigational Alzheimer’s Agent in Mild Disease
Tuesday, June 27, 2017 | Dementia & Cognitive Disorders
You must be logged in to leave a comment.